XSHE
002412
Market cap681mUSD
Sep 30, Last price
9.07CNY
Name
Hunan Hansen Pharmaceutical Co Ltd
Chart & performance
P/E
23.04
P/S
4.39
EPS
0.39
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
3.10%
Revenues
1.04b
+3.41%
Net income
198m
-10.05%
CFO
245m
+87.62%
Dividend
Jun 16, 20260.3 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hunan Hansen Pharmaceutical Co., Ltd. is engaged in the manufacturing and global distribution of a wide array of both traditional Chinese and Western pharmaceutical products. The company's diverse offerings are available in numerous formats, including injectables, oral liquids, tablets, capsules, granules, syrups, decoctions, tinctures, and pills. Its primary operational base is located in Yiyang, China.
Key people
Aihua Liu
Vice President · since 2023
Zhijun Liu
Vice President, Chief Production Officer · since 2023
Hua Yang
Vice President · since 2020
Jianghong Dai
Chief Financial Officer, Vice President, Secretary of the Board · since 2023
Lingsong Ao
Vice President, Director · since 2023
Jianjun Fu
Vice President, Director · since 2020
Zhengqing Liu
Chairman of the Board, President · since 2023
Gaoyun Hu
Independent Director · since 2020
Bingyang Liu
Independent Director · since 2023
Jinsong Xia
Independent Director · since 2020
Ping Zhan
Independent Director
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||